Journal ArticleDOI
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.
About:
This article is published in International Journal of Cardiology.The article was published on 2014-09-20. It has received 32 citations till now. The article focuses on the topics: Xanthine oxidase & Xanthine.read more
Citations
More filters
Journal ArticleDOI
Oxidative Stress and Human Hypertension: Vascular Mechanisms, Biomarkers, and Novel Therapies
Augusto C. Montezano,Maria Dulak-Lis,Sofia Tsiropoulou,Adam Harvey,Ana M. Briones,Rhian M. Touyz +5 more
TL;DR: Current knowledge on oxidative stress in vascular pathobiology and implications in human hypertension are reviewed, biomarkers to assess the redox state in the clinic are discussed, novel strategies to inhibit ROS production are highlighted, and how lifestyle modifications promote vascular health by reducing oxidative stress is summarized.
Journal ArticleDOI
Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
TL;DR: The potential benefit of using anti-inflammatory treatments in diabetes and important issues that should be addressed prior to implementation of such therapeutic approaches are discussed.
Journal ArticleDOI
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
TL;DR: It is of major clinical interest to define what role the anti-inflammatory effects of these glucose-lowering agents may play in the prevention of macrovascular and microvascular diabetic complications and to distinguish between anti- inflammation effects resulting from better glucose control and potential anti- inflammatory effects related to intrinsic actions of the pharmacological class.
Journal ArticleDOI
Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
TL;DR: The crosstalk between AGEs-RAGE axis and DPP-4-incretin system in the development and progression of diabetes-associated disorders and its therapeutic intervention, especially focusing on diabetic vascular complications is summarized.
Journal ArticleDOI
The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
TL;DR: The ongoing Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus (CARMELINA®) study will definitively assess the renal effects of this DPP-4 inhibitor.
References
More filters
Journal ArticleDOI
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Wook Kim,Josephine M. Egan +1 more
TL;DR: Two new classes of drugs based on incretin action have been approved for lowering blood glucose levels in type 2 diabetes (T2DM) and an incretIn enhancer (sitagliptin, which is a DPP4 inhibitor).
Journal ArticleDOI
Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities.
Ramón Rodrigo,Rodrigo Fernández-Gajardo,Rodrigo Gutiérrez,José Manuel Matamala,Rodrigo Carrasco,Andres Miranda-Merchak,Walter Feuerhake +6 more
TL;DR: The mechanisms involved in ROS generation, the role of oxidative stress in the pathogenesis of ischemic stroke, and the novel therapeutic strategies to be tested to reduce the cerebral damage related to both ischemia and reperfusion are focused on.
Journal ArticleDOI
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
TL;DR: Investigation of the potency, selectivity, mechanism, and duration of action of BI 1356 in vitro and in vivo and compared it with other DPP-4 inhibitors found it to have the potential to become the first truly once-a-day D PP-4 inhibitor for the treatment of type 2 diabetes.
Journal ArticleDOI
Reactive oxygen species in myocardial reperfusion injury: from physiopathology to therapeutic approaches.
TL;DR: Clinical trials could be improved by the standardisation of the methods to measure oxidative stress and their impact on prognosis outcome, and the clinical approach used has so far been inadequate.
Journal ArticleDOI
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin- like growth factor II receptor
TL;DR: The present study suggests that AGE-RAGE-induced ROS generation stimulates the release of DPP-4 from ECs, which could in turn act on ECs directly via the interaction with M6P/IGF-IIR, further potentiating the deleterious effects of AGEs.
Related Papers (5)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica,Deepak L. Bhatt,Deepak L. Bhatt,Eugene Braunwald,P. Gabriel Steg,Jaime A. Davidson,Boaz Hirshberg,Peter Öhman,Robert Frederich,Stephen D. Wiviott,Elaine B. Hoffman,Matthew A. Cavender,Jacob A. Udell,Nihar R. Desai,Ofri Mosenzon,Darren K. McGuire,Kausik K. Ray,Lawrence A. Leiter,Itamar Raz +18 more